Dis-Chem Pharmacies Limited Overview
Dis-Chem is South Africa's second-largest retail pharmacy chain by store count and, on its own measure, the largest retail pharmacy group by dispensary market share. It operates a vertically integrated model that combines big-box pharmacy-anchored health, beauty and wellness retail (316 Dis-Chem pharmacies and 42 Dis-Chem Baby City stores at February 2026) with a pharmaceutical wholesale and distribution arm. That arm (CJ Distribution / Dis-Chem Distribution) supplies the group's own stores, more than 1,600 independent pharmacies and 280 The Local Choice franchise pharmacies. FY2026 revenue was R42.8bn. Under its first non-founder CEO, Rui Morais, the group is repositioning from "pharmacy retailer" to "integrated healthcare provider and funder". This rests on in-store nurse clinics, the Health Hub store format, health-funding products (Dis-Chem Health medical insurance via Kaelo, and Dis-Chem Life), the data-led Better Rewards loyalty programme, and an in-house innovation unit, X, bigly labs. The strategy compresses near-term earnings: FY2026 HEPS fell 17.3%. It also differentiates the group from its larger, higher-margin rival, Clicks Group.
What the company does
Dis-Chem runs two reportable operating segments, as defined in its FY2025 audited annual financial statements (note 6):
-
Retail. Dis-Chem pharmacy stores retail pharmaceuticals and a wide range of health and beauty products. The segment also includes pharma-logistic services (Pharma-Logistical Solutions), oncology pharmacy (Dis-Chem Oncology, 50% owned but consolidated through board control), and the specialist baby retail business (Dis-Chem Baby City and the former Baby Boom stores). Since FY2026, Dis-Chem Health (medical insurance and gap cover distribution) has also been reported within core retail.
-
Wholesale. CJ Wholesale / CJ Pharmaceutical Enterprises and Dis-Chem Distribution wholesale pharmaceutical, health and beauty products. Customers are: (a) the group's own retail stores, which provide most wholesale revenue and are eliminated on consolidation; (b) independent pharmacies (more than 1,600, per the FY2026 integrated report as reported by Business Report); and (c) franchisees of The Local Choice (TLC) pharmacy brand (280 franchise stores at February 2026).
Company's own description
The FY2025 AFS describe Retail as "the Dis-Chem stores, retailers of pharmaceutical and a variety of health and beauty products, as well as pharma-logistic services and oncology", and Wholesale as "the CJ Wholesale and Dis-Chem Distribution businesses, wholesalers of pharmaceutical and a variety of health and beauty products". The FY2026 results (29 May 2026) recast the corporate purpose. The aim is to position the group as "South Africa's healthcare authority", playing a "dual role of healthcare provider and funder", with healthcare delivery creating "a defensive moat that secures the traditional retail basket". The FY2026 integrated report (July 2026) describes an integrated operating model combining retail, wholesale, digital and healthcare services.
Revenue model
| Revenue / income stream | Nature | Evidence |
|---|---|---|
| Product sales (retail) | Transactional sales of dispensary (regulated Single Exit Price plus dispensing fee), front-shop health, beauty, nutrition and baby products | FY2025 retail category mix: dispensary 36%, personal care & beauty 28%, healthcare & nutrition 22%, baby 8%, other 6% (FY2025 AFS note 7) |
| Product sales (wholesale, external) | Pharmaceutical distribution to independents and TLC franchisees on 30–60-day credit terms | External wholesale revenue R5.60bn in FY2025 (AFS note 6) |
| Supplier-funded "other income" | Advertising and marketing income, data and administration fees, commissions, franchise fees | FY2025 group other income R3.35bn: advertising & marketing R1.24bn; data & admin fees R1.73bn; commission R69m; franchise income R59m; IFRS 16 property-release gain R104m (AFS note 8) |
| Services | Clinic services (nurse-led consultations, vaccinations, state-contracted family planning and baby vaccinations), virtual GP access, pharma logistics | Disclosed qualitatively; revenue n/d |
| Insurance / funding | Distribution of Dis-Chem Health medical insurance and gap cover (via the Kaelo associate) and Dis-Chem Life (50% JV, equity-accounted) | Kaelo FY2025 revenue R1.18bn (100% basis), group share of profit R13.5m; Dis-Chem Life share of loss R50.2m in FY2026 |
| Loyalty / retail media | Better Rewards, a supplier-funded instant-discount programme with 140+ participating brands and Capitec co-funding | R410m returned to customers in the first 17 weeks (trading update, 20 February 2026) |
The model is overwhelmingly product-based. Subscription and licensing revenue is immaterial or n/d. The economically important nuance is that supplier income (rebates, advertising, data fees) is a large share of total income. Rebate accounting was the sole key audit matter in Forvis Mazars' FY2025 audit report.
Value-chain position
Dis-Chem sits across two links of the South African private pharmaceutical value chain: wholesale distribution and retail dispensing/merchandising. It is now adding primary-care delivery (clinics, Health Hubs) and health funding (insurance distribution and a life-insurance JV). It does not manufacture medicines. Through Origin Brands (held via the 50% Geniob JV) and its private-label ranges it participates in brand ownership.
Customers and end-markets
Retail consumers: Mass-to-middle-income South Africans. About 9 million legacy Benefit Card members were migrated to Better Rewards in October 2025. The company cited around 15 million customers (Business Day, April 2025) and 1.2 million customers living with chronic conditions (Dis-Chem Life launch, March 2025).
Medical-scheme patients and members: Dispensary revenue depends on medical-scheme benefit cycles; January benefit availability materially lifted retail sales in FY2025 (trading update, February 2025).
Independent pharmacies and TLC franchisees: Wholesale customers.
Suppliers / brand owners: Buyers of retail media, data and promotional services.
The State: Contracted family-planning and baby-vaccination services delivered free to patients through Dis-Chem clinics (Business Day, April 2026).
Independent characterisation
Dis-Chem is best understood as a scale-driven, low-margin health retailer (group operating margin 4.3–5.4% over FY2022–FY2026) whose economics rest on three things: big-box store productivity, wholesale procurement scale, and supplier-funded income. Its rival Clicks earns a materially higher trading margin (9.8% in FY2025) from a far larger, smaller-format pharmacy network (780 pharmacies) with deeper private-label penetration. Dis-Chem's strategic answer is not to imitate Clicks. It aims to "own the patient" through health funding, clinics and data-led loyalty. The bet is still early: FY2026 required R445m of ecosystem and non-recurring spend, and management expects X, bigly labs to turn net-positive only in FY2027.
Strategy
Stated strategy (themes from SENS FY2025, FY2026 and the FY2026 integrated report)
Dis-Chem's strategy has two layers.
Eight strategic areas (introduced under Morais in FY2024/FY2025): store footprint and space growth; people (staffing frameworks); working capital; digital (re-platforming, "digital health ownership"); analytics (commercialising health-consumption data); integrated health ecosystem; wholesale share gains; and cost discipline. Interim FY2025 materials explicitly list "Digital: re-platforming and building capability to ensure digital health ownership" and "Leveraging Analytics: … commercialise health consumption data".
The ecosystem thesis (FY2026). The group aims to transition "from pharmacy retailer to integrated healthcare provider". The stated purposes are increasing access to and reducing the cost of care; playing the "dual role of healthcare provider and funder"; and using healthcare delivery as a "defensive moat that secures the traditional retail basket" (SENS FY2026). The CEO acknowledged in the FY2026 integrated report that shareholders who invested for the earnings track record "have seen a year of disappointing reported results" (Business Report, 3 July 2026).
Initiative register (last 24 months)
| Initiative | Date | Description | Targets / metrics disclosed |
|---|---|---|---|
| Staffing framework 1.0 | FY2024–FY2025 | Standardised store staffing mix | Like-for-like retail employee costs −0.2% in FY2025; +3.5% in FY2026 |
| Staffing framework 2.0 | FY2026–FY2027 | Next phase of retail labour model | In progress (SENS FY2026 outlook) |
| Space growth | FY2025–FY2027 | Store roll-out | 137,000 m² three-year target; 39 stores planned FY2026 (31 delivered); 35 planned FY2027 |
| Working-capital unlock | FY2026 | Excess stock reduction | R500m target; inventory flat YoY and inventory days 90.5 → 86.4 |
| Dis-Chem Life | Launched Feb–Mar 2025 | Life, funeral and Protector cover JV with OneSpark platform; Guardrisk-underwritten | R155.9m for 50%; FY2026 JV loss R100.4m (Dis-Chem share R50.2m) |
| X, bigly labs | Launched Nov 2025 (established FY2025) | Innovation, data and AI hub | R330m FY2026 investment (incl. R27m Dis-Chem Life); net positive returns expected FY2027 |
| Better Rewards + Capitec | 21 Oct 2025 | Instant-discount loyalty; Capitec +5% | R410m returned in 17 weeks; c. 550,000 new shoppers; volume market share +1.1pp across core retail categories in FY2026 |
| Analytically-led promotional engine | FY2026 | Data-informed promotions | Credited with part of the retail total income margin uplift to 31.1% |
| Health Hub / Store of the Future | 6–7 May 2026 | Integrated clinic, pharmacy and cover format | All new stores from 1 Aug 2026; existing stores revamped over time |
| App relaunch | 7 May 2026 | Clinic booking, digital scripts | E-commerce relaunch still pending at May 2026 |
| Head-office operating model restructure | Apr 2026 onward | Section 189 for just over 500 roles; c. 200 new roles in underinvested departments | Earnings call cited 545 affected employees; under 2.4% of workforce |
| Strategic partnerships with non-competing brands | FY2026 priority | Access to mass-market South Africa (Capitec is the first major example) | — |
| People: "20,000 purpose-aligned ambassadors" | FY2026–FY2027 | Employee health and rewards programme | Staff receive +10% Better Rewards boost |
Management guidance and medium-term targets
FY2027 guidance (SENS FY2026, 29 May 2026): 35 new retail pharmacies; Store of the Future roll-out; X, bigly labs to be net-positive in FY2027; consumer to remain constrained, with fuel-price increases cited.
First 10 weeks of FY2027 (1 March–19 May 2026): group revenue +9.0%; retail +8.8%; external wholesale +10.4%; total income margin 32.0%.
Financial targets: the earlier 30% total income margin target was met in FY2023. No formal medium-term revenue, margin or ROIC targets were located in the sources reviewed.
Dividend policy: 40% of headline earnings.
Products & Services
Retail segment
| Offering | Description | Key capabilities / specifications | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| Dis-Chem Pharmacy (big-box format) | Pharmacy-anchored health, beauty and wellness stores; the core format since 1978 | Dispensary; front shop of beauty, personal care, vitamins and supplements, sports nutrition, baby, health appliances and fitness equipment; in-store clinic. 316 stores at Feb 2026 (incl. 3 in Namibia, 3 in Botswana per FY2025 AFS) | Mass to upper-middle income consumers and medical-scheme members | Ongoing; 31 stores opened or acquired in FY2026 | Retail margin; dispensary regulated by Single Exit Price (SEP) plus a regulated dispensing fee |
| Health Hub / "Store of the Future" | New format integrating pharmacy, clinic and health-cover advice around a central Hub | Digital queue ticketing; multiple script submission channels (app, digital); upgraded clinic with nurse-led consults, virtual GP access, diagnostic pre-assessment room and clinic care assistant; centralised admin; advisors selling medical, gap, funeral and life cover | Same base, plus uninsured and under-insured patients | First store Melrose Arch, 6–7 May 2026; mandatory for new stores from 1 Aug 2026 | Format; monetised through retail, clinic and insurance distribution |
| Dis-Chem Clinics | In-store primary-care clinics | Nurse consultations, vaccinations, chronic screening, HealthCheck (feeds Better Rewards Health Rating); state-contracted family planning and baby vaccinations free to patients | Retail customers, policyholders, public patients | Long-standing; upgraded 2026 | Fee-for-service; contract income from the State; detailed pricing n/d |
| Virtual GP / Healthforce | Nurse-assisted telemedicine | Virtual doctor consultations within clinics | Uninsured / low-cost primary care | Healthforce 87.5% subsidiary (acquisition date n/d) | Per-consult fee (n/d) |
| Dis-Chem Baby City | Specialist baby retail format (Baby City acquired Jan 2021; Baby Boom Mar 2022) | Prams, car seats, nursery, consumables, clothing | Parents and expectant parents | 42 stores at Feb 2026 (down from 54 in FY2023 after rationalisation) | Retail margin |
| Dis-Chem Oncology | Specialist oncology pharmacy | Oncology medicine dispensing and services | Oncology patients and funders | 50% owned, consolidated (control via board appointments) | Regulated medicine pricing |
| Pharma-Logistical Solutions | Pharma logistics service business inside Retail | Logistics services (detail n/d) | Pharma companies / funders | — | Service fees |
| Better Rewards | Collaborative, brand-funded instant-discount loyalty programme developed by X, bigly labs | 10% instant discount on 140+ participating brands; +5% with a Capitec card (15% total); ≥20% for Dis-Chem Health / gap / Life policyholders, up to 100% savings (capped at R3,000/month) linked to HealthCheck rating; staff +10% boost; rewards script adherence | c. 9m migrated members plus new shoppers (c. 550,000 new shoppers in the first 17 weeks; 1.1m lapsed or new by May 2026) | Live 21 Oct 2025, replacing the Benefit Card | Supplier-funded discounts; R115m non-recurring cost to retire the points scheme |
| Dis-Chem app & e-commerce | Online retail, script submission, clinic booking | Clinic booking in 30-minute slots; digital scripts; collection in store | Omnichannel customers | Revamped app relaunched 7 May 2026; broader e-commerce relaunch still "soon to be relaunched" per FY2026 SENS | Retail pricing |
| Private label / exclusive brands | Own and controlled brands (including via the Origin Brands / Geniob JV) | Range details n/d | Value-seeking shoppers | — | Retail margin |
| Tony Ferguson weight-loss | Health and lifestyle ranges (25% associate) | Weight-management products | Weight-loss consumers | 25% acquired FY2023 | Retail |
Health funding and insurance
| Offering | Description | Key capabilities | Target customer | Launch | Pricing model |
|---|---|---|---|---|---|
| Dis-Chem Health (medical insurance and gap cover) | Affordable primary-care medical insurance and gap cover distributed by Dis-Chem; Kaelo (25% associate) houses the product portfolio | Primary health insurance, gap cover; occupational clinics and the AskNelson wellbeing platform within Kaelo | Uninsured and under-insured employed consumers | Kaelo stake from Nov 2021; product growth reported FY2025 | Monthly premiums (n/d); Kaelo FY2025 revenue R1.18bn and profit R54.1m (100% basis) |
| Dis-Chem Life | Life, funeral and "Protector" cover sold under the Dis-Chem brand; FSP 50594; underwritten by Guardrisk Life Ltd (FSP 76) | AI-driven underwriting; premiums linked to HealthCheck outcomes; at least 20% Better Rewards discount for policyholders; free annual clinic HealthCheck | Retail customers, including 1.2m with chronic conditions | Launched Feb–Mar 2025 (CEO Greg Smith) | Risk-rated monthly premiums; JV loss R100.4m in FY2026 (100% basis) |
Wholesale segment
| Offering | Description | Capabilities | Target customer | Pricing model |
|---|---|---|---|---|
| CJ Distribution / Dis-Chem Distribution | National pharmaceutical wholesale | Distribution centres in Midrand and Longmeadow (Gauteng), Cape Town and KwaZulu-Natal; c. 100,000 m² of DC space in Gauteng alone (Daily Investor, Sept 2026); SAP-hosted stock management | Own stores, >1,600 independent pharmacies, TLC franchisees | Wholesale margin plus logistics and data fees; 30–60-day credit |
| Nelspruit Pharmaceutical Wholesaler | Regional wholesaler (Evening Star Trading 204) | Mpumalanga regional distribution | Independents | Wholesale margin |
| The Local Choice (TLC) franchise | Pharmacy franchise brand for independent owners | Buying power, brand, systems; 280 stores at Feb 2026 | Independent pharmacist-owners | Franchise fees (group franchise income R59m in FY2025) plus wholesale supply |
| The Pharmacy Development Academy (70%) | Pharmacy training | Skills development | Pharmacists and assistants | — |
| Retail media and data (DC Media, CJ Marketing, Brandwacht Marketing) | Supplier advertising, data and administration services | In-store and digital media; data and admin fees | FMCG and pharma suppliers | Fees (FY2025 data & admin fees R1.73bn; advertising & marketing R1.24bn across segments) |
Innovation unit
| Offering | Description | Status |
|---|---|---|
| X, bigly labs | In-house innovation, data and technology hub (Melrose Arch; executive head Aliyah Allie). Built Better Rewards, the analytically-led promotional engine and the Health Hub format | Established FY2025–FY2026; formal launch Nov 2025; R330m front-loaded investment in FY2026 (including R27m Dis-Chem Life marketing and operating costs); net positive returns expected FY2027 |
Financial Narrative
Income statement: notes and sources
Sources: FY2023 reviewed results (FY2022–FY2023); FY2025 AFS (FY2024–FY2025); FY2026 from SENS FY2026 commentary, S&P Global Market Intelligence (via StockAnalysis) and Daily Investor (29 May 2026). FY2026 total income, other income, net financing costs, share of associates, EBITDA, D&A, profit for the year and headline earnings are derived as noted.
Margin profile (%)
Growth metrics. Revenue CAGR FY2022–FY2026 was 8.9% (derived: 42,826 / 30,407 over four years). Basic HEPS CAGR over the same period was 3.5%. Operating profit CAGR was 4.7%. Revenue has therefore compounded at more than twice the rate of per-share earnings. This gap is the central analytical fact of the five-year record.
Commentary on income-statement trends
FY2022 (inflection out of COVID). Revenue grew 15.7%, helped by COVID-19 vaccination and testing services and by acquisitions (Baby City, Medicare). The total income margin was only 28.9% because mix favoured low-margin dispensary and COVID-related revenue. Operating margin was 5.1%.
FY2023 (margin step-up, earnings peak on the old model). Revenue growth slowed to 7.4% as COVID services fell away (8.4% retail growth excluding COVID effects). The total income margin jumped 220bp to 31.1%, reaching the group's 30% target "eighteen months sooner than initially anticipated" (FY2023 results). Drivers were the normalisation of category mix, better trade terms and higher service income. HEPS rose 17.4% to 116.5c. Cost pressure was already visible: retail expenses excluding depreciation grew 15.8%, IT costs 32%, and diesel for load-shedding generators rose 65% to R91m.
FY2024 (the earnings stall). Revenue grew a strong 11.1% (wholesale +13.3%), but HEPS fell 1.6% to 114.6c. The total income margin slipped to 30.7%. Payroll ran ahead of sales, finance costs rose 26% on the new property loans, and load-shedding costs persisted. The H1 FY2024 HEPS decline of 17.2% (Reuters/Zawya) triggered the "staffing framework 1.0" programme. FY2024 was also the CEO-transition year.
FY2025 (operating leverage restored). Revenue grew 8.0% and operating profit 18.3%. EPS and HEPS each rose 20.0%; excluding the R103.7m Midrand property gain, HEPS rose 12.3%. The SENS explicitly attributes the improvement to staffing framework 1.0: like-for-like retail employee costs fell 0.2% while comparable store sales rose 4.1%. Retail total income margin rose 60bp to 30.3% on higher transactional gross margin and trade terms.
FY2026 (deliberate earnings sacrifice). Revenue growth accelerated to 9.3%, with retail +9.0% (comparable +5.3%, driven by Better Rewards) and wholesale +13.1%. Operating profit fell 11.9% and HEPS 17.3%. Three factors explain the fall: (1) R445m of ecosystem and non-recurring expense; (2) total expenses up 13.0%, with retail expenses up 15.7% including X, bigly labs headcount and depreciation/amortisation of new technology and stores; and (3) a R50.2m share of Dis-Chem Life's loss. Wholesale margin compressed (total income margin c. 7.2% versus 8.2% excluding the property gain in FY2025) on mix and procurement costs. Underlying retail delivered positive operating leverage: like-for-like sales +5.3% versus like-for-like payroll +3.5%, and retail total income margin up 80bp to 31.1%. In the first 10 weeks of FY2027, the group total income margin reached 32.0% (SENS FY2026 outlook).
Balance sheet
Sources: FY2023 results (FY2022–FY2023); FY2025 AFS (FY2024–FY2025); S&P Global Market Intelligence via StockAnalysis (FY2026, cross-checked to filed FY2022–FY2025 balances).
Notes: the FY2026 overdraft / current-loan split is n/d. S&P reports FY2026 short-term debt of R1,949m and a current portion of long-term debt of R235m. FY2026 receivables per S&P (R3,745m) include other receivables and are defined slightly differently from the filed trade and other receivables line.
Balance-sheet commentary. The defining trend is the move from an asset-light, leased estate to owned logistics real estate. Over FY2022–FY2025, Dis-Chem bought its Cape Town and KZN warehouses (R223m), the 63,000 m² Longmeadow DC (R502m) and the Midrand DC/HQ (R520m), largely with dedicated term loans: R455m from Standard Bank at 3-month JIBAR + 1.44% (5-year bullet), R502m and R650m facilities, and in FY2026 a further R500m two-year bullet extendable to three years. Bank debt excluding leases nearly tripled, from R1.3bn (FY2022) to R3.7bn (FY2026). Lease liabilities fell as owned properties replaced leases. Overdraft usage has risen persistently (R1.32bn at FY2025), and the FY2026 increase in net finance costs was attributed to "the additional overdraft facility being used". Equity has compounded from R3.4bn to R5.7bn, so gearing including leases has edged down (debt/equity 1.33× to 1.17×). Net debt/EBITDA including leases has risen to about 2.0×.
Cash flow
Sources: company cash flow statements (FY2022–FY2025). FY2026 operating cash flow, capex and debt flows from S&P via StockAnalysis, with capex cross-checked to SENS FY2026 (R1.1bn total: R730m expansion, R374m maintenance). The OCF row adds back dividends paid to the company's reported "cash flow from operating activities" (which deducts dividends) so it is comparable with standard OCF definitions.
Cash-flow commentary. Cash generation has been volatile and dominated by working capital and property purchases. FY2023 and FY2025 both saw large inventory build-ups. In FY2025 inventory rose R743m and inventory days reached 90.5 because of new stores and the timing of the SEP buy-in, and free cash flow was negative before leases once the Midrand property was bought. FY2026 marks a clear improvement: inventory was held flat (+R3m) despite 31 new stores, inventory days fell to 86.4, and operating cash flow rose 68% to R2.32bn. This matches the "R500 million working capital unlock" priority set in May 2025. Buybacks are limited to treasury shares for employee schemes; there has been no general repurchase programme.
Ratio analysis
All ratios are analyst-computed from the tables above unless stated. ROE uses average attributable equity (FY2021 attributable equity of R2,909m derived from the FY2023 statement of changes in equity). ROIC = operating profit × (1 − 27% statutory rate) ÷ (closing total equity + net debt including leases).
For comparison, S&P Global (via StockAnalysis, 30 August 2026) reports trailing ROE of 18.96%, ROIC of 11.63%, a current ratio of 1.11, debt/equity of 1.17 and interest coverage of 3.34×, consistent with the analyst calculations.
Ratio commentary. Returns have de-rated in two steps: the cost inflation of FY2024 and the ecosystem investment of FY2026. ROE fell from about 27–28% to 18%. That is still respectable for a low-margin retailer but far below Clicks' 49.2% ROE (Clicks FY2025). ROIC has drifted from 15–16% to about 11%, partly by design: owned property and technology intangibles have expanded invested capital ahead of their returns. The working-capital cycle is structurally favourable, because creditor days exceed inventory days and the group carries net working capital of only about 24 days. This is a key funding advantage of the wholesale-retail model.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products / services | Key legal entities (per AFS note 4) |
|---|---|---|---|
Retail | Dis-Chem pharmacy stores; Dis-Chem Baby City / Baby Boom; Dis-Chem Oncology; pharma-logistic services; clinics; Dis-Chem Health (since FY2026 reported within core retail) | Dispensary, personal care & beauty, healthcare & nutrition, baby care, clinic services | Dis-Chem Pharmacies Ltd (most stores); store subsidiaries (e.g. Dis-Chem Ballito Junction 75%, Dis-Chem Krugersdorp 51%, Dis-Chem Thavhani Mall 65%); Pure Pharmacy Holdings; Healthforce (87.5%); Superstrike Investment 56; Fairy Tales Boutiques; Pharma-Logistical Solutions; The Local Choice Pty Ltd; DC Media |
Wholesale | CJ Wholesale and Dis-Chem Distribution | Pharmaceutical, health and beauty wholesale; logistics; franchise support | Dis-Chem Distribution; CJ Pharmaceutical Enterprises; Evening Star Trading 204 (Nelspruit Pharmaceutical Wholesaler); CJ Marketing; Bemax International; Brandwacht Marketing; property companies (CT Distribution Centre, KZN Warehouse, Eleadora, Columbia Falls Properties 7) |
Intergroup / consolidation | Elimination of wholesale sales to own retail stores | — | — |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Retail revenue (ZAR Mn) | 27,108 | 28,883 | 31,693 | 33,570 | 36,600 |
Wholesale revenue incl. intersegment (ZAR Mn) | 21,911 | 24,179 | 27,390 | 30,099 | 34,000 |
Wholesale revenue to external customers (ZAR Mn; FY2026 derived = group less retail) | 3,298 | 3,780 | 4,591 | 5,603 | 6,226 |
Intersegment elimination (ZAR Mn; FY2026 derived) | -18,613 | -20,399 | -22,800 | -24,497 | -27,774 |
Group revenue (ZAR Mn) | 30,407 | 32,664 | 36,283 | 39,172 | 42,826 |
Retail revenue growth YoY (%) | — | 6.5 | 9.7 | 5.9 | 9.0 |
Wholesale revenue growth YoY (%) | — | 10.4 | 13.3 | 9.9 | 13.1 |
Retail share of group revenue (%) | 89.2 | 88.4 | 87.3 | 85.7 | 85.5 |
Wholesale external share of group revenue (%) | 10.8 | 11.6 | 12.7 | 14.3 | 14.5 |
Retail total income (ZAR Mn; FY2026 derived at +12.2%) | 7,641 | 8,666 | 9,409 | 10,155 | 11,394 |
Wholesale total income (ZAR Mn; FY2026 derived ex prior-year property gain) | 1,639 | 2011 | 2,229 | 2,559 | 2,455 |
Retail total income margin (%) | 28.2 | 30.0 | 29.7 | 30.3 | 31.1 |
Wholesale total income margin (%) | 7.5 | 8.3 | 8.1 | 8.5 | 7.2 |
Retail EBITDA (ZAR Mn) | 2,160 | 2,339 | 2,357 | 2,597 | — |
Wholesale EBITDA (ZAR Mn) | 229 | 428 | 519 | 663 | — |
Retail operating profit (ZAR Mn) | 1,417 | 1,432 | 1,376 | 1,575 | — |
Wholesale operating profit (ZAR Mn) | 115 | 310 | 393 | 519 | — |
Retail operating margin (%) | 5.2 | 5.0 | 4.3 | 4.7 | — |
Wholesale operating margin (%) | 0.5 | 1.3 | 1.4 | 1.7 | — |
Retail profit before tax (ZAR Mn) | 1,122 | 1,088 | 1,038 | 1,232 | — |
Wholesale profit before tax (ZAR Mn) | 99 | 327 | 337 | 392 | — |
Retail capex (ZAR Mn) | 326 | 578 | 456 | 663 | — |
Wholesale capex (ZAR Mn) | 52 | 512 | 571 | 739 | — |
Segment Margins & Growth (%) and Operating Metrics (count)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Retail pharmacy stores at year-end (count; FY2022 and FY2024 derived from openings/closures) | 253 | 258 | 268 | 285 | 316 |
Retail baby stores at year-end (count; FY2022 derived) | 34 | 54 | 54 | 45 | 42 |
Comparable pharmacy store revenue growth (%) | — | 3.3 | — | 4.1 | 5.3 |
TLC franchise stores at year-end (count) | 147 | 171 | 205 | 240 | 280 |
Dispensary share of retail revenue (%) | 36 | 36 | 35 | 36 | — |
Personal care & beauty share of retail revenue (%) | 26 | 27 | 28 | 28 | — |
Healthcare & nutrition share of retail revenue (%) | 24 | 22 | 21 | 22 | — |
Baby care share of retail revenue (%) | 8 | 8 | 9 | 8 | — |
Other share of retail revenue (%) | 6 | 7 | 7 | 6 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (ZAR Mn) | 30,407 | 32,664 | 36,283 | 39,172 | 42,826 |
Revenue growth YoY (%) | 15.7 | 7.4 | 11.1 | 8.0 | 9.3 |
Cost of sales (ZAR Mn) | 23,576 | 25,076 | 28,067 | 30,372 | 33,417 |
Gross profit (ZAR Mn) | 6,830 | 7,587 | 8,217 | 8,800 | 9,409 |
Other income (ZAR Mn; FY2026 derived) | 1,961 | 2,587 | 2,908 | 3,347 | 3,796 |
Total income (ZAR Mn; FY2026 derived from reported +8.7%) | 8,792 | 10,174 | 11,124 | 12,148 | 13,205 |
Other expenses incl. D&A (ZAR Mn) | 7,252 | 8,430 | 9,345 | 10,044 | 11,350 |
Depreciation & amortisation incl. right-of-use (ZAR Mn; FY2026 per S&P) | 855 | 1,002 | 1,062 | 1,145 | 1,260 |
EBITDA, company definition (ZAR Mn; FY2026 derived = operating profit + D&A) | 2,395 | 2,769 | 2,886 | 3,270 | 3,113 |
Operating profit (ZAR Mn) | 1,539 | 1,744 | 1,779 | 2,104 | 1,853 |
Finance costs, gross (ZAR Mn) | 325 | 370 | 466 | 521 | 554 |
Net financing costs (ZAR Mn; FY2026 derived from reported +3.3%) | 313 | 350 | 440 | 491 | 507 |
Share of profit of associates & JVs (ZAR Mn; FY2026 derived) | 1 | 23 | 45 | 20 | 48 |
Profit before tax (ZAR Mn) | 1,227 | 1,417 | 1,385 | 1,634 | 1,395 |
Taxation (ZAR Mn) | 337 | 389 | 364 | 414 | 359 |
Profit for the year (ZAR Mn; FY2026 derived, c. R1.04bn per Daily Investor) | 890 | 1,028 | 1,020 | 1,219 | 1,036 |
Profit attributable to equity holders (ZAR Mn) | 853 | 1,000 | 984 | 1,180 | 979 |
Headline earnings (ZAR Mn; FY2026 derived from HEPS × weighted shares) | 853 | 1,001 | 983 | 1,179 | 974 |
Basic EPS (ZAR cents) | 99.2 | 116.3 | 114.7 | 137.6 | 114.2 |
Diluted EPS (ZAR cents) | 99.2 | 116.3 | 114.7 | 137.5 | — |
Basic HEPS (ZAR cents) | 99.2 | 116.5 | 114.6 | 137.5 | 113.7 |
Dividend per share, total declared (ZAR cents) | 39.7 | 46.57 | 45.74 | 54.83 | 45.34 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 22.5 | 23.2 | 22.6 | 22.5 | 22.0 |
Total income margin (%) | 28.9 | 31.1 | 30.7 | 31.0 | 30.8 |
EBITDA margin, company definition (%) | 7.9 | 8.5 | 8.0 | 8.3 | 7.3 |
Operating margin (%) | 5.1 | 5.3 | 4.9 | 5.4 | 4.3 |
Pre-tax margin (%) | 4.0 | 4.3 | 3.8 | 4.2 | 3.3 |
Net margin, attributable (%) | 2.8 | 3.1 | 2.7 | 3.0 | 2.3 |
Effective tax rate (%) | 27.5 | 27.5 | 26.3 | 25.4 | 25.7 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | 14,075 | 15,516 | 17,501 | 19,257 | 20,738 |
Property, plant & equipment incl. right-of-use (ZAR Mn) | 3,689 | 4,429 | 4,800 | 5,297 | 5,826 |
Goodwill (ZAR Mn) | 791 | 874 | 930 | 926 | 948 |
Other intangible assets (ZAR Mn) | 419 | 397 | 405 | 522 | 792 |
Goodwill & intangibles combined (ZAR Mn) | 1,210 | 1,270 | 1,335 | 1,448 | 1,740 |
Investments in associates & JVs (ZAR Mn) | 183 | 194 | 208 | 356 | 564 |
Inventories (ZAR Mn) | 5,759 | 6,357 | 7,163 | 7,905 | 7,908 |
Trade & other receivables (ZAR Mn) | 2,160 | 2,583 | 2,732 | 3,313 | 3,745 |
Cash & cash equivalents (ZAR Mn) | 706 | 287 | 884 | 585 | 500 |
Bank overdraft (ZAR Mn) | 425 | 448 | 851 | 1,318 | — |
Loans payable, current (ZAR Mn) | 399 | 797 | 488 | 575 | — |
Loans payable, non-current (ZAR Mn) | 479 | 501 | 1,282 | 1,679 | 1,510 |
Bank debt incl. overdraft, excl. leases (ZAR Mn) | 1,303 | 1,746 | 2,621 | 3,572 | 3,694 |
Lease liabilities, total (ZAR Mn) | 3,204 | 3,228 | 3,068 | 2,664 | 2,943 |
Total debt incl. leases (ZAR Mn) | 4,507 | 4,974 | 5,689 | 6,236 | 6,637 |
Net debt excl. leases (ZAR Mn) | 597 | 1,459 | 1,737 | 2,987 | 3,194 |
Net debt incl. leases (ZAR Mn) | 3,802 | 4,687 | 4,806 | 5,650 | 6,138 |
Trade & other payables (ZAR Mn) | 5,788 | 6,104 | 6,864 | 7,246 | — |
Total equity incl. NCI (ZAR Mn) | 3,386 | 3,932 | 4,475 | 5,229 | 5,694 |
Equity attributable to parent (ZAR Mn) | 3,324 | 3,900 | 4,472 | 5,218 | 5,645 |
Working capital, current assets less current liabilities (ZAR Mn) | 1,340 | 1,098 | 1,740 | 1,767 | 1,178 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash inflow from trading operations (ZAR Mn) | 2,413 | 2,783 | 2,878 | 3,223 | — |
Movement in working capital (ZAR Mn) | 45 | -718 | -175 | -924 | — |
Operating cash flow after interest and tax, before dividends (ZAR Mn) | 1,836 | 1,320 | 1,890 | 1,377 | 2,317 |
Capex to maintain operations (ZAR Mn) | 140 | 723 | 158 | 942 | 374 |
Capex to expand operations (ZAR Mn) | 237 | 367 | 869 | 461 | 730 |
Total capex (ZAR Mn) | 377 | 1,090 | 1,027 | 1,402 | 1,104 |
Free cash flow = OCF less capex (ZAR Mn) | 1,459 | 230 | 863 | -25 | 1,213 |
Lease liability repayments (ZAR Mn) | 510 | 565 | 587 | 641 | — |
Free cash flow after lease repayments (ZAR Mn) | 949 | -335 | 276 | -666 | — |
Dividends paid incl. to NCI (ZAR Mn) | 459 | 466 | 424 | 472 | — |
Treasury share purchases (ZAR Mn) | 12 | 29 | 65 | 33 | — |
Acquisitions of businesses & JVs, net of cash (ZAR Mn) | 266 | 44 | 55 | 156 | — |
Bank loans raised (ZAR Mn) | 537 | 1,317 | 1,201 | 1,372 | 629 |
Bank loan and lease repayments combined (ZAR Mn) | 942 | 1,491 | 1,329 | 1,525 | 1,541 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on average equity (%) | 27.4 | 27.7 | 23.5 | 24.4 | 18.0 |
Return on closing assets (%) | 6.3 | 6.6 | 5.8 | 6.3 | 5.0 |
ROIC, closing invested capital (%) | 15.6 | 14.8 | 14.0 | 14.1 | 11.4 |
Current ratio (x) | 1.18 | 1.13 | 1.19 | 1.17 | 1.11 |
Debt to equity incl. leases (x) | 1.33 | 1.26 | 1.27 | 1.19 | 1.17 |
Net debt incl. leases to EBITDA (x) | 1.59 | 1.69 | 1.67 | 1.73 | 1.97 |
Net debt excl. leases to EBITDA (x) | 0.25 | 0.53 | 0.60 | 0.91 | 1.03 |
Interest coverage, operating profit / gross finance costs (x) | 4.7 | 4.7 | 3.8 | 4.0 | 3.3 |
Asset turnover, revenue / closing assets (x) | 2.16 | 2.11 | 2.07 | 2.03 | 2.07 |
Inventory days (company-reported) | 88.6 | 88.2 | 88.1 | 90.5 | 86.4 |
Creditor days (company-reported) | — | — | 93.2 | 93.9 | 92.3 |
Net working capital days (company-reported) | 26.5 | 28.1 | 21.7 | 24.8 | 24.4 |
Operating Metrics (count)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Namibia stores (count) | — | — | — | 3 | — |
Botswana stores (count) | — | — | — | 3 | — |
Total retail stores, pharmacy + baby (count) | 287 | 312 | 322 | 330 | 358 |
TLC franchise stores, South Africa (count) | 147 | 171 | 205 | 240 | 280 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing share price at FY end (ZAR) | 34.62 | 27.05 | — | — | — |
12-month share price high (ZAR) | 38.20 | 38.45 | — | — | — |
12-month share price low (ZAR) | 21.81 | 27.03 | — | — | — |
Basic HEPS (ZAR cents) | 99.2 | 116.5 | 114.6 | 137.5 | 113.7 |
Interim DPS (ZAR cents) | 19.5 | 28.1 | 23.25 | 26.98 | 29.42 |
Final DPS (ZAR cents) | 20.2 | 18.45 | 22.49 | 27.85 | 15.92 |
Total DPS (ZAR cents) | 39.7 | 46.57 | 45.74 | 54.83 | 45.34 |
Net asset value per share (ZAR cents) | 393.7 | 457.4 | 521 | 609 | 659 |
Shares in issue incl. treasury (millions) | 860.08 | 860.08 | 860.08 | 860.08 | 860.08 |
Share Price History
| Period | Approximate price change | Basis |
|---|---|---|
1 year | −15.3% | S&P 52-week change to 28 Aug 2026 |
About 3.5 years | −4.7% | R27.05 (28 Feb 2023) to R25.78 (14 Sep 2026) |
About 5 years | −17.5% | R31.25 (11 Jun 2021) to R25.78 (14 Sep 2026) |
Valuation Multiples
| Multiple | Dis-Chem at R25.78 (14 Sep 2026, analyst-derived) | Dis-Chem at R28.80 (S&P, 28 Aug 2026) | Clicks Group |
|---|---|---|---|
Market cap (ZAR Bn) | 22.1 | 24.66 | 88.0 (31 Aug 2025) |
Enterprise value incl. leases (ZAR Bn) | 28.2 | 30.84 | — |
P/E on basic EPS (x) | 22.6 | 25.24 | n/d (current) |
Forward P/E (x) | — | 19.96 | — |
EV/EBITDA (x; company EBITDA incl. IFRS 16) | 9.1 | 10.10 (S&P EBITDA basis) | — |
EV/Sales (x) | 0.66 | 0.72 | — |
P/B (x) | 3.9 | 4.33 | — |
Dividend yield (%) | 1.76 | 1.53 | — |
Analyst Conclusions
Management guidance (SENS FY2026, 29 May 2026)
-
Consumer expected to remain constrained, with fuel-price increases a named headwind.
-
35 new retail pharmacies in FY2027 (8 trading by 19 May 2026); Store of the Future design for all stores with beneficial occupation from 1 August 2026.
-
X, bigly labs expected to generate net positive returns in FY2027.
-
Restructured operating model with about 200 new roles in underinvested functions.
-
Staffing framework 2.0; digital and e-commerce relaunch.
-
Trading for 1 March–19 May 2026: revenue +9.0%; retail +8.8%; external wholesale +10.4%; total income margin 32.0%.
Consensus expectations
Consensus (S&P, August 2026) implies revenue growth of about 9.6% a year and EPS growth of about 21.9% a year over three years. That is effectively a recovery to and beyond FY2025 earnings by FY2027–FY2028. The forward P/E of about 20× at R28.80 implies a forward EPS of about 144c (derived), above the FY2025 peak of 137.6c.
Bull case
-
The FY2026 earnings dip is investment, not erosion. Adjusted group PBT rose 20.1% and core retail PBT 27.1% excluding R445m of ecosystem and non-recurring spend. R115m of that spend was explicitly non-recurring, and X, bigly labs is guided to be net-positive in FY2027. A normalisation of these costs alone could restore HEPS toward the FY2025 level.
-
Margin and cash inflection already visible. The total income margin reached 32.0% in early FY2027 (versus 30.8% in FY2026), Better Rewards drove a 1.1pp volume share gain, and operating cash flow rose 68% to R2.32bn on flat inventory. A low-margin retailer with improving gross economics and disciplined working capital can deliver outsized EPS leverage; consensus expects about 22% annual EPS growth.
-
Valuation is undemanding for a structural grower. At about R25.78, the stock trades on about 22.6× depressed trailing EPS, about 0.66× EV/Sales and about 9× EV/EBITDA. Revenue has compounded at 8.9% and the store base is growing about 10% a year (35 stores on 316). The founder-family overhang is clearing, and the board is now independent-majority.
Bear case
-
Structural profitability gap persists. Operating margin has never exceeded 5.4% in five years while Clicks earns 9.8%. Wholesale margin fell about 100bp in FY2026. Each new initiative (clinics, insurance, loyalty discounts, technology) adds cost before revenue, and ROIC has declined from about 15.6% to about 11.4%.
-
The ecosystem bet is unproven and competitively exposed. Dis-Chem Life lost R100.4m in its first full year against entrenched insurers and Capitec Life. Better Rewards depends on continued supplier funding. Management's "net positive in FY2027" is a target, not a track record, and FY2026 already missed the earnings trajectory implied by FY2025.
-
Balance sheet and shareholder-structure risks. Bank debt excluding leases nearly tripled to R3.7bn, interest cover fell to 3.3×, and the dividend was cut 17%. About 217m shares now sit with non-executive heirs who sold about R642m in early 2026. The share price trend (−15% over 52 weeks, below both moving averages) reflects these concerns.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| H1 FY2027 interim results | 30 Oct 2026 | HEPS growth versus H1 FY2026 (73.8c); total income margin (32.0% run-rate?); X, bigly labs cost run-rate; Dis-Chem Life losses |
| Clicks Group FY2026 results | c. late Oct 2026 | Relative pharmacy share and margin trends |
| Better Rewards anniversary | From 21 Oct 2026 | Like-for-like growth once the launch base effect laps |
| Health Hub roll-out | FY2027 | Number of new and revamped stores; revenue per m²; clinic utilisation |
| Section 189 conclusion | H2 2026 | Final headcount reduction; cost savings versus the 200 new hires |
| Saltzman heir share sales / block trades | Ongoing | Overhang release; new strategic holders |
| SEP determination | Annual (typically Q1 calendar year) | Size of the permitted price increase and its effect on dispensary and wholesale margins |
| Trading update | c. Feb 2027 | Festive-season and January medical-benefit trading |
| FY2027 results | c. late May 2027 | Delivery of the "net positive" X, bigly labs return; dividend recovery |
| Debt and covenants | Ongoing | Overdraft usage; refinancing of the R455m bullet (c. FY2028) |
Concluding analyst verdict
Dis-Chem enters FY2027 at the most consequential juncture since its 2016 listing. The founding Saltzman family, whose discount-pharmacy concept built a R42.8bn revenue group from a 75 m² corner shop, has fully exited both management and the board. In its place is a professional executive team led by Rui Morais. It has made an explicit, capital-intensive bet that the group can earn superior long-run returns by becoming an integrated healthcare provider and funder rather than a pure pharmacy retailer.
The evidence is genuinely mixed. On the positive side, the core engine is working. Revenue grew 9.3% in FY2026 with comparable pharmacy sales up 5.3%. Retail total income margin expanded to 31.1%, and the early-FY2027 group margin of 32.0% suggests Better Rewards is accretive rather than margin-dilutive. Working capital discipline produced the strongest operating cash flow in five years. Adjusted for ecosystem investment, earnings grew about 18–20%.
On the negative side, reported earnings fell 17% and the dividend was cut. Leverage has risen materially to fund owned logistics property. Wholesale margins compressed. The insurance JV is loss-making in a market of formidable incumbents. Most importantly, the five-year record shows revenue compounding at nearly 9% while HEPS compounded at only 3.5%. That pattern suggests the company has historically struggled to convert scale into per-share value, and Clicks continues to earn roughly double the margin and ROE.
The share price, down about 15% over 12 months to about R25.78, prices in considerable scepticism. The investment case now turns on a single, testable proposition: whether the FY2026 investment year is followed by visible operating leverage in H1 FY2027 (reporting 30 October 2026). Delivery would validate the strategy and the consensus recovery path. A second year of cost growing ahead of income would reinforce the bear thesis that Dis-Chem's ecosystem ambitions dilute rather than enhance shareholder returns.
APPENDIX: SOURCES
Primary filings (JSE SENS / company)
-
Dis-Chem FY2023 Reviewed Annual Condensed Consolidated Results (FY2023 and FY2022 data): https://senspdf.jse.co.za/documents/2023/jse/isse/dcpe/FY23.pdf
-
Dis-Chem FY2025 Group and Company Audited Annual Financial Statements (FY2025 and FY2024 data): https://senspdf.jse.co.za/documents/2025/jse/isse/dcpe/FY25.pdf
-
Dis-Chem FY2025 Audited Annual Consolidated Results announcement, 30 May 2025: https://senspdf.jse.co.za/documents/SENS_20250530_S505511.pdf
-
Dis-Chem FY2026 Audited Annual Consolidated Results announcement, 29 May 2026 (text via InsidEntity): https://www.insidentity.com/dis-chem-pharmacies-audited-annual-consolidated-results-for-the-twelve-months-ended-28-february-2026/ ; original PDF: https://senspdf.jse.co.za/documents/2026/jse/isse/dcpe/FY26.pdf
-
Dis-Chem FY2024 results (via thevault.exchange): https://thevault.exchange/?get_group_doc=6262%2F1717133841-SENS20240531S489352.pdf
-
Dis-Chem HY2025 Interim Results: https://senspdf.jse.co.za/documents/2024/jse/isse/dcpe/HY25.pdf
-
Dis-Chem HY2026 Interim Results: https://senspdf.jse.co.za/documents/2025/jse/isse/dcpe/HY26.pdf
-
Trading update, 21 Feb 2025: https://senspdf.jse.co.za/documents/SENS_20250221_S501068.pdf
-
CEO and CFO succession, 15 May 2023: https://senspdf.jse.co.za/documents/SENS_20230515_S475117.pdf
-
Kaelo acquisition / trading statement, 18 Oct 2021: https://senspdf.jse.co.za/documents/SENS_20211018_S452569.pdf
-
Clicks Group FY2025 results: https://senspdf.jse.co.za/documents/SENS_20251023_S512272.pdf ; analyst presentation: https://www.clicksgroup.co.za/wp-content/uploads/2025/10/CGL-2025-Annual-results-analyst-presentation.pdf
Market data
-
S&P Global Market Intelligence via StockAnalysis (income statement, balance sheet, cash flow, statistics, price history): https://stockanalysis.com/quote/jse/DCP/statistics/ ; https://stockanalysis.com/quote/jse/DCP/financials/balance-sheet/ ; https://stockanalysis.com/quote/jse/DCP/history/
-
Quartr AGM 2026 summary: https://quartr.com/events/dis-chem-pharmacies-limited-dcp-agm-2026_F98KcWim
-
FilingReader (FY2026 results; Allan Gray stake): https://filingreader.com/news-wire/johannesburg/2026-05-29/dis-chem-adjusted-profit-climbs-20-to-r18bn ; https://filingreader.com/news-wire/johannesburg/2025-09-11/allan-gray-clients-boost-stake-in-dis-chem-pharmacies
News and secondary sources
-
Daily Investor: R5 billion in five years (29 May 2026): https://dailyinvestor.com/retail/136483/r5-billion-in-five-years-say-goodbye-to-dis-chem-as-you-know-it/
-
Daily Investor: From R10,000 and one pharmacy to R22 billion and 343 stores (20 Sep 2026): https://dailyinvestor.com/retail/155762/from-r10000-and-one-pharmacy-to-r22-billion-and-343-stores/
-
Daily Investor: Dis-Chem's billionaire founder resigns: https://dailyinvestor.com/retail/145094/dis-chems-billionaire-founder-resigns/
-
Daily Investor: Billionaire's son resigns from Dis-Chem board: https://dailyinvestor.com/retail/144329/billionaires-son-resigns-from-dis-chem-board/
-
Daily Investor: Capitec gives South African pharmacy giant a boost: https://dailyinvestor.com/retail/120707/capitec-gives-south-african-pharmacy-giant-a-boost/
-
Daily Investor: Major South African pharmacy giant is crushing it (H1 FY2026): https://dailyinvestor.com/retail/108223/major-south-african-pharmacy-giant-is-crushing-it/
-
Daily Investor: Dis-Chem rolling out new stores (Health Hub): https://dailyinvestor.com/retail/133031/dis-chem-rolling-out-new-stores-that-promise-to-end-long-pharmacy-queues/
-
Daily Investor: Ivan Saltzman share restructuring (June 2025): https://dailyinvestor.com/?p=91407
-
Daily Investor: Dis-Chem founder sells R1.4 billion in shares: https://dailyinvestor.com/business/43106/dis-chem-founder-sells-r1-4-billion-in-shares/
-
Daily Investor: Dis-Chem showed strong growth – but it came at a cost: https://dailyinvestor.com/?p=65002
-
Daily Investor: Dis-Chem loses R1.9 billion after no-whites letter: https://dailyinvestor.com/retail/5470/dis-chem-loses-r1-9-billion-after-no-whites-letter/
-
BusinessTech: End of an era for Dis-Chem (29 May 2026): https://businesstech.co.za/news/business/861885/end-of-an-era-for-dis-chem/
-
BusinessTech: Saul Saltzman board resignation (20 Jul 2026): https://businesstech.co.za/news/?p=866827
-
BusinessTech: Better Rewards / Capitec (10 Oct 2025): https://businesstech.co.za/news/business/839545/new-dis-chem-rewards-programme-launching-in-south-africa-with-a-big-boost-for-capitec-customers/
-
BusinessTech: Capitec deal gives Dis-Chem 550,000 new customers: https://businesstech.co.za/news/business/851650/capitec-deal-gives-dis-chem-550000-new-customers/
-
BusinessTech: Dis-Chem announces retrenchments (24 Apr 2026): https://businesstech.co.za/news/finance/858415/dis-chem-announces-retrenchments-in-south-africa/
-
BusinessTech: Big earnings boost for Dis-Chem (30 May 2025): https://businesstech.co.za/news/business/826157/big-earnings-boost-for-dis-chem/
-
BusinessTech: Clicks opening hundreds more stores (pharmacy counts): https://businesstech.co.za/news/business/840769/clicks-opening-hundreds-more-stores-in-south-africa/
-
Business Day: Dis-Chem begins retrenchment consultations (24 Apr 2026): https://www.businessday.co.za/companies/2026-04-24-dis-chem-begins-retrenchment-consultations-as-it-restructures-head-office/
-
Business Day: Coronation takes commanding stake in Dis-Chem (31 Jan 2024): https://www.businessday.co.za/bd/companies/retail-and-consumer/2024-01-31-coronation-takes-commanding-stake-in-dis-chem/
-
Business Report: Dis-Chem's strategic investments (3 Jul 2026): https://businessreport.co.za/companies/2026-07-03-dis-chems-strategic-investments-position-it-for-future-growth-in-south-africa/
-
Business Report: Saltzman family selling off the family silver (Feb 2024): https://businessreport.co.za/companies/2024-02-05-saltzman-family-selling-off-the-family-silver-at-dis-chem
-
TimesLIVE: Dis-Chem's new Health Hub (9 May 2026): https://www.timeslive.co.za/news/business/2026-05-09-dis-chems-new-health-hub-to-transform-primary-care/
-
TimesLIVE: Dis-Chem targets 34 new stores (29 May 2026): https://www.timeslive.co.za/news/business/2026-05-29-dis-chem-targets-34-new-stores/
-
Yahoo Finance / GuruFocus: FY2026 earnings call highlights: https://finance.yahoo.com/sectors/healthcare/articles/dis-chem-pharmacies-ltd-jse-010238482.html
-
Cover magazine: Dis-Chem Life launch (4 Mar 2025): https://www.cover.co.za/news/dis-chem-make-life-insurance-more-accessible-and-affordable
-
Dis-Chem Life regulatory footer (Guardrisk underwriting): https://dischemlife.co.za/?p=2325
-
Capitec: Dis-Chem Better Rewards boost: https://www.capitecbank.co.za/rewards/spend-better/dis-chem/
-
Zawya / Reuters: H1 FY2024 earnings decline: https://www.zawya.com/en/world/africa/south-africas-dis-chem-profit-falls-but-expects-stronger-second-half-oe50kt8x
-
Namibian Sun: B-BBEE certificate (Nov 2022): https://namibiansun.com/international-ns/no-wonder-dis-chem-boss-wrote-that-memo2022-11-01
-
Wikipedia: Dis-Chem (history, IPO, Competition Tribunal fine): https://en.wikipedia.org/wiki/Dis-Chem
-
CB Insights: Dis-Chem profile (patent filings, IPO date): https://www.cbinsights.com/investor/dis-chem
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education | Age |
|---|---|---|---|---|---|
Rui Morais | Chief Executive Officer, executive director | CEO since 1 Jul 2023; joined 2010; previously CFO | Group CFO before succession; led FY2025 operating-leverage recovery and the ecosystem strategy | Chartered Accountant, CA(SA) (FY2023 results) | — |
Julia (JD) Pope | Chief Financial Officer, executive director | CFO since 1 Jul 2023; joined 2017 as executive head of finance | 19 years of retail experience at appointment (May 2023) | — | 42 at May 2023 (c. 45 now) |
Aliyah Allie | Executive Head, X, bigly labs | FY2026– | Leads the innovation unit (Better Rewards, Health Hub) | — | — |
Greg Smith | CEO, Dis-Chem Life (50% JV) | 2025– | Life-insurance platform founder side (OneSpark) | — | — |
Prescribed officers (FY2025 AFS) | BI Epstein, CJ Williams, CR Fairweather, CA Swanepoel, TJ Ponter, R Govender, Z Dindar, Q Cronje (KS Sterling listed as a comparative) | — | Titles n/d in sources reviewed | — | — |
Board of Directors
| Name | Role | Independence | Committees (where disclosed) | Tenure / notes |
|---|---|---|---|---|
Larry (LM) Nestadt | Chairman | Independent non-executive (classified independent in FY2023 results) | — | Chairman since at least the 2016 listing; indirect interest of 500,000 shares (FY2025 AFS) |
Ahmed Coovadia | Non-executive director | Independent | Audit & Risk | Indirect interest 162,162 shares |
Joe (JS) Mthimunye | Non-executive director | Independent | Chairman, Audit & Risk Committee | Indirect interest 81,162 shares |
Anushka (A) Sithebe | Non-executive director | Independent | Audit & Risk | — |
Hlengiwe Masondo | Non-executive director | Independent | Audit & Risk | Appointed 14 Jul 2022 |
KKD (Kgomotso) Kobue | Non-executive director | Listed as independent (FY2023) | Audit & Risk (non-voting member) | — |
Rui Morais | CEO | Executive | — | Board member since at least FY2023 |
Julia Pope | CFO | Executive | — | Since 1 Jul 2023 |
Board of Directors by Director
| Director | Change | Effective date | Source |
|---|---|---|---|
Saul (SE) Saltzman | Executive director → non-independent NED | 27 Feb 2026 | SENS FY2026 |
Saul Saltzman | Resigned as NED | 17 Jul 2026 | Company statement, 20 Jul 2026 |
Stanley (SRN) Goetsch | Retired as executive director after 42 years | 30 Jun 2026 | SENS FY2026; BusinessTech |
Ivan (IL) Saltzman | Retired as executive director; became NED (announced as Deputy Chairman) | 30 Jun 2026 | SENS FY2026; BusinessTech |
Ivan Saltzman | Resigned from board | 23 Jul 2026 | Daily Investor (company statement) |
Lynette Saltzman | Stepped down as executive director (operational role in beauty) | 14 Jul 2022 | FY2023 results |
MJ Bowman | Resigned as NED | 14 Jul 2022 | FY2023 results |
Major Shareholders
| Holder | Stake | Date / basis | Source |
|---|---|---|---|
Coronation Asset Management (clients) | 29.83% | Feb 2024, after buying 50m shares from Ivlyn | Business Day, 31 Jan 2024; Daily Investor |
Ivlyn Local Investment Holdings (Saltzman vehicle) | 29.31% before June 2025; c. 4.1% after (derived) | 217m shares distributed 20 Jun 2025 | Daily Investor |
Mark Saltzman (direct) | c. 11–12% (derived) | Received c. half of 217m shares (reported as R3.4bn each); sold c. R321m in Jan–Feb 2026 | Daily Investor; BusinessTech |
Dan Saltzman (direct) | c. 11–12% (derived) | As above | As above |
Public Investment Corporation (PIC) | Just above 10% | Nov 2023 | Business Day, 31 Jan 2024 |
Allan Gray (clients) | 5.4574% | 11 Sep 2025 (crossed notifiable threshold) | FilingReader (SENS) |
Royal Bafokeng Holdings | 6.6% | As reported Aug 2024 | Cape Times, 5 Aug 2024 |
Stansha | 4.6% | As reported Aug 2024 | Cape Times, 5 Aug 2024 |
SRN Goetsch (indirect) | 29.9m shares (c. 3.5%) | FY2025 AFS (down from 39.9m in FY2024) | FY2025 AFS |
CJ Williams (prescribed officer, indirect) | 11.2m shares (c. 1.3%) | FY2025 AFS | FY2025 AFS |
BI Epstein (prescribed officer, indirect) | 9.1m shares (c. 1.1%) | FY2025 AFS | FY2025 AFS |
Institutional ownership (aggregate) | 68.22% | Aug 2026 | S&P via StockAnalysis |
Insider ownership (aggregate) | 4.77% | Aug 2026 | S&P via StockAnalysis |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Dis-Chem | Scale indicators (where verified) |
|---|---|---|---|
Retail pharmacy / health & beauty | Clicks Group (Clicks, UniCare, The Body Shop, Sorbet, M-Kem) | Market leader; smaller-format, higher-density estate; higher private-label share | FY2025 (Aug YE) turnover R47.8bn (+5.3%); trading margin 9.8%; 990+ stores; 780 pharmacies; retail pharmacy market share 24.0%; DHEPS 1,361.7c (+14.1%); ROE 49.2%; market cap R88.0bn (Clicks FY2025) |
Retail pharmacy (grocery-anchored) | Shoprite Holdings (MediRite) | In-supermarket pharmacies with grocery footfall | 144 MediRite pharmacies (BusinessTech, Oct 2025); pharmacy revenue n/d |
Retail pharmacy (grocery-anchored) | SPAR Group (Pharmacy at SPAR) | Franchised in-store pharmacies | 125 pharmacies (BusinessTech); revenue n/d |
Independent pharmacy networks | Alpha Pharm | Buying group / brand for independents; competes with TLC | 350+ pharmacies (BusinessTech) |
Independent pharmacy networks | Link Pharmacy | Independent pharmacy network | 300+ pharmacies (BusinessTech) |
Pharmaceutical wholesale | United Pharmaceutical Distributors (UPD, Clicks Group) | Largest competitor to CJ Distribution in full-line wholesale | UPD trading margin 3.3% (Clicks FY2025); turnover growth 5.1% |
Health & beauty retail | Woolworths, Foschini/TFG beauty, Edgars, online marketplaces (e.g. Takealot) | Competition in beauty and personal care | — |
Baby retail | Clicks (baby), PEP/Ackermans (Pepkor), online marketplaces | Commoditisation of baby consumables | — |
Primary-care / clinics | Clicks clinics; GP practices; occupational health providers | Competes with Dis-Chem Clinics and Health Hubs | — |
Health funding / insurance | Discovery, Old Mutual, Momentum, Sanlam, OUTsurance, Capitec Life | Competes with Dis-Chem Life and Dis-Chem Health | n/d (large, entrenched insurers) |
Peer Comparison FY2026
| Metric | Dis-Chem (FY2026, Feb YE) | Clicks Group (FY2025, Aug YE) | Shoprite – MediRite | SPAR – Pharmacy at SPAR |
|---|---|---|---|---|
Revenue (ZAR Bn) | 42.8 | 47.8 | n/d (pharmacy not reported separately) | — |
Revenue growth (%) | 9.3 | 5.3 | — | — |
Operating / trading margin (%) | 4.3 (5.4 adjusted) | 9.8 | — | — |
Total income margin (%) | 30.8 | 31.1 | — | — |
HEPS growth (%) | −17.3 | +14.1 (diluted) | — | — |
ROE (%) | c. 18 | 49.2 | — | — |
Pharmacies (count) | 316 | 780 | 144 | 125 |
R&D intensity (% of revenue) | n/d (ecosystem spend 1.0%) | — | — | — |
Dividend payout policy | 40% of HEPS | 65% payout (FY2025) | — | — |



